Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
973–1008
Headlines
2643
Sources here
13
Companies here
18
Current section United States Medical Instruments & Supplies news

Chronological news

Earlier headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Neville Rodie & Shaw Inc. Sells 2,802 Shares of Intuitive Surgical, Inc. $ISRG

Neville Rodie & Shaw Inc. reduced its stake in Intuitive Surgical (NASDAQ:ISRG) by 30.7% in the second quarter, selling 2,802 shares and retaining 6,320 shares valued at $2.51 million. Despite this, Intuitive Surgical reported strong quarterly earnings of $2.80 per share and revenue of …

ISRG main company
Sharemaestro market context Price below Trend Line 52 weeks -17.1% · Next-week setup negative 41.3% ISRG stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Arkadios Wealth Advisors Purchases New Stake in DENTSPLY SIRONA Inc. $XRAY

Arkadios Wealth Advisors recently acquired a new stake of 74,961 shares in DENTSPLY SIRONA Inc. (NASDAQ:XRAY), valued at approximately $870,000. Despite this new investment and insider purchases totaling over $200,000 in June, analyst sentiment remains cautious, with an average "Hold" rating and a target …

XRAY main company
Sharemaestro market context Price below Trend Line 52 weeks -18.8% XRAY stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Expanded Medline Sinclair Tech Distribution in Canada Could Be A Game Changer For DENTSPLY SIRONA (XRAY)

DENTSPLY SIRONA recently announced an expanded partnership with Medline Sinclair for full technology portfolio distribution in Canada, effective September 1, 2026. This move could significantly scale DENTSPLY SIRONA's digital dentistry solutions in the Canadian market. The announcement comes ahead of the Q2 2026 earnings …

XRAY main company
Sharemaestro market context Price below Trend Line 52 weeks -18.8% XRAY stored weekly price path from 22 Aug 2025 to 14 Aug 2026

NexGel, Inc Revenue Breakdown – BOATS:NXGLW

NexGel, Inc (NXGLW) reported a total revenue of $11.42 million USD last year. The majority of this revenue, $8.61 million USD, was generated by its NexGel segment, an increase from $6.63 million USD in the prior year. The United States was the primary contributor …

NXGL main company
Sharemaestro market context New activity signal 52 weeks -75.6% · Next-week setup negative 44.5% NXGL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

(PLSE) Movement as an Input in Quant Signal Sets

This article from Stock Traders Daily discusses Pulse Biosciences Inc (NASDAQ: PLSE), highlighting strong sentiment across all horizons and compelling upside potential. It presents three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, tailored for different …

PLSE main company
Sharemaestro market context Trend signal active 52 weeks +161.2% PLSE stored weekly price path from 22 Aug 2025 to 14 Aug 2026

OraSure Technologies Q2 Earnings Call Highlights

OraSure Technologies (NASDAQ: OSUR) reported strong Q2 results, exceeding revenue guidance with $30.6 million, driven by increased public-health demand and growth in diagnostic and sample-management products. The company achieved key regulatory milestones, including FDA clearance for its Colli-Pee Dx urine collection kit and Emergency …

OSUR main company
Sharemaestro market context Trend signal active 52 weeks +28.0% · Next-week setup negative 40.2% OSUR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Envista Holdings Corp 2026: Revenue $730.5M, EPS $0.33— 10-Q Summary

Envista Holdings Corp (NVST) reported strong results for the 2026 quarter, with revenue reaching $730.5M and diluted EPS of $0.33, indicating significant year-over-year growth. Net income more than doubled to $53.7M. The company experienced broad-based revenue growth, driven by volume and pricing increases, particularly …

NVST main company
Sharemaestro market context Trend signal started 52 weeks +29.2% NVST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Fire loss hits Medline Inc. (Nasdaq: MDLN) profit despite 11.6% sales growth

Medline Inc. (Nasdaq: MDLN) reported an 11.6% increase in Q2 2026 net sales to $7.7 billion, and an 11.1% increase for the first six months to $15.0 billion. Despite strong sales growth, net income for Q2 dropped 58.3% to $139 million and 42.3% for …

MDLN main company
Sharemaestro market context Price below Trend Line 35 weeks -14.2% · Next-week setup negative 37.7% MDLN stored weekly price path from 19 Dec 2025 to 14 Aug 2026

LeMaitre Vascular (NASDAQ:LMAT) Sets New 1-Year Low on Analyst Downgrade

LeMaitre Vascular (NASDAQ:LMAT) shares hit a new 52-week low after Wells Fargo downgraded its price target and maintained an equal-weight rating, amidst a broader shift in analyst sentiment to "Hold." The company's Q2 revenue and EPS, despite year-over-year growth, missed analyst expectations, leading to …

LMAT main company
Sharemaestro market context Price below Trend Line 52 weeks -17.3% · Next-week setup positive 60.5% LMAT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Medline Earnings: Solid Sales Momentum Overshadowed by Margin Concerns, but Selloff Overblown

Medline reported strong revenue and adjusted EBITDA growth of 12% and 13% respectively in the second quarter. Despite raising organic sales growth outlook, the adjusted EBITDA margin outlook was lowered, leading to a 13% drop in shares. The author suggests the selloff might be …

MDLN main company
Sharemaestro market context Price below Trend Line 35 weeks -14.2% · Next-week setup negative 37.7% MDLN stored weekly price path from 19 Dec 2025 to 14 Aug 2026

LeMaitre Vascular, Inc. Stock 12‑Month Price Target Cut to $116.25, Implies 10% Upside

LeMaitre Vascular, Inc.'s average 12-month price target has been lowered from $118.75 to $116.25 by 8 analysts, suggesting a 10% upside from its Aug. 4 closing price. The consensus rating remains a "Buy" from 9 analysts, with 5 recommending Buy and 4 recommending Hold.

LMAT main company
Sharemaestro market context Price below Trend Line 52 weeks -17.3% · Next-week setup positive 60.5% LMAT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Envista Holdings Corp (NVST) (Q2 2026) Earnings Call Highlights: Strong Core Growth and Raised ...

Envista Holdings Corp (NVST) reported strong Q2 2026 results, with core sales up 5%, adjusted EBITDA increasing 28%, and adjusted EPS growing 58%. The company raised its full-year 2026 guidance due to broad-based growth across segments and geographies. However, anticipated headwinds include a Q4 …

NVST main company
Sharemaestro market context Trend signal started 52 weeks +29.2% NVST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Kestra Medical Technologies CCO Ford sells $151,140 in stock

Kestra Medical Technologies' Chief Commercial Officer, Alfred J. Ford Jr., sold 6,275 common shares totaling $151,140 on August 4, 2026. This transaction was non-discretionary, intended to cover tax withholding obligations from restricted stock unit vesting. Following the sale, Mr. Ford Jr. still beneficially owns …

KMTS main company
Sharemaestro market context Trend signal started 52 weeks +50.8% KMTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Solventum (NYSE: SOLV) to separate $1.4B Health Information Systems arm

Solventum (NYSE: SOLV) announced its intention to separate its Health Information Systems (HIS) business, which generated $1.4 billion in net sales in 2025. This move is part of a broader portfolio optimization strategy to transform Solventum into a more focused MedTech company. The company …

SOLV main company
Sharemaestro market context Trend signal active 52 weeks +20.4% · Next-week setup negative 34.7% SOLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context